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Psychological Factors in Asthma
Ryan J. Van Lieshout, MD and Glenda MacQueen, MD, PhD, FRCPC
Asthma has long been considered a condition in which psychological factors have a role. As in many illnesses, psychological
variables may affect outcome in asthma via their effects on treatment adherence and symptom reporting. Emerging evidence
suggests that the relation between asthma and psychological factors may be more complex than that, however. Central cognitive
processes may influence not only the interpretation of asthma symptoms but also the manifestation of measurable changes in
immune and physiologic markers of asthma. Furthermore, asthma and major depressive disorder share several risk factors and have
similar patterns of dysregulation in key biologic systems, including the neuroendocrine stress response, cytokines, and
neuropeptides. Despite the evidence that depression is common in people with asthma and exerts a negative impact on outcome,
few treatment studies have examined whether improving symptoms of depression do, in fact, result in better control of asthma
symptoms or improved quality of life in patients with asthma.
Key words: asthma, depression, pathophysiology, treatment
P
sychological factors may influence the symptoms and
management of asthma, and numerous pathways may
contribute to the links between asthma and psychiatric
disease states such as depression. The notion that
emotional stress can precipitate or exacerbate acute and
chronic asthma
1 has been recognized anecdotally for
many years. Psychological barriers, such as faulty
symptom attribution, adoption or rejection of the sick
role, and low self-esteem, may negatively impact treat-
ment adherence. Conversely, the presence of a chronic
and potentially life-threatening illness may exert enough
stress that an anxiety or depressive disorder emerges in
vulnerable patients. As a consequence, epidemiologic
associations between major depressive disorder (MDD)
and asthma might be apparent but not reflect a shared
pathophysiologic vulnerability. Alternatively, there may be
aspects of dysregulation in key biologic systems, such as
the neuroendocrine stress response or cytokine system,
that predispose people to both asthma and psychiatric
illness independent of the psychological impact of one
chronic illness on the other. More provocatively, perhaps,
there may be components of central or peripheral nervous
system dysfunction that predispose people to asthma or
worsen the course of asthma independent of behavioural
response style or the experience of illness-related stress or
depression.
The purpose of this review is to summarize the
disparate reports in the literature that point toward an
association between asthma and psychological factors. The
review has four primary components. The first briefly
examines the evidence that psychological interventions
can be beneficial in the treatment of asthma, ignoring
whether the patients involved in the intervention have any
a priori evidence of psychological distress or impaired
psychosocial function. The second part of the review
addresses the limited literature on whether the presence of
psychiatric illness, primarily major depression or an
anxiety disorder (AD), has a negative impact on asthma
outcome and whether treatment of the psychiatric
condition improves these outcomes and also considers
the epidemiologic evidence of an association between
asthma and depression. The third section considers the
multiple biologic factors that could contribute to a shared
vulnerability for depression and asthma as several key
systems share patterns of dysregulation across these
illnesses. Finally, we discuss a nascent literature examining
the central nervous system (CNS) correlates of an
asthmatic response.
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A number of studies have examined the efficacy of
psychological therapies at improving various aspects of
asthma control or quality of life. These studies have been
reviewed for both adults
2 and children
3,4 and are not
discussed in detail here. Because psychotherapy models
can be grouped according to their theoretical frameworks
or methods of operation, the various approaches are
briefly discussed below:
1. Behavioural therapies focus on identifying the pro-
cesses by which behaviour has been learned via
association, reward, or observation and modifying
behaviour using methods such as systematic desensi-
tization, selective reinforcement, and positive model-
ing. The behaviour itself, rather than the underlying
motivations, is the focus of behavioural interventions.
Dahl found positive results following behavioural
therapy when school absenteeism and use of as-needed
medications were the outcome measures.
5
2. Cognitive therapies focus on identification and con-
structive management of incorrect and damaging
thoughts, such as perceptions of helplessness or
inappropriate fear of asthma attack, that can trigger
episodes. Information (eg, about the relationships
between anxiety and bronchoconstriction) also targets
cognitions.
3. Cognitive behaviour therapy (CBT) incorporates the
key elements of both behavioural and cognitive models
and is currently used more frequently than either
cognitive or behavioural therapies alone. Two studies
measuring asthma knowledge as an outcome reported
benefits of CBT,
6,7 and CBT has been reported to have
a positive effect on self-efficacy measures.
4. Relaxation techniques are generally conducted with or
without biofeedback and were the focus of several earlier
studies of psychological interventions in asthma.
Relaxation techniques control stress and anxiety, which,
in asthma, may improve breathing and respiratory
function. Such programs generally include progressive
relaxation, autogenic training, which focuses on attend-
ing to bodily feelings and mentally controlling them, and
hypnosisordeeprelaxation,whichmaybeinducedusing
mental imagery. This is often accompanied by auto-
suggestion to create positive thoughts and feedback of
biologic indicators, which the subject must control via
relaxation. Alexander and Weingarten measured the
effect of relaxation therapy on peak expiratory flow and
found effects favouring the treatment group compared
with the control group.
8,9 In addition, self-hypnosis-
assisted relaxation reduced emergency room visits, again
in a single study that also found that self-reports of
asthma improved in the self-hypnosis group.
10 In
contrast, hospital admission rates were not decreased
following biofeedback,
11,12 nor were self-hypnosis rates
or use of as-needed medications,
13 but emergency room
visits were in a single study.
11 The results from these
studies highlight the variability in outcome measures
employed and the difficulty of understanding these
studies in a systematic manner given this variability.
5. Psychodynamic psychotherapies attempt to uncover
the emotional issues and response styles that drive
patients to behave in maladaptive ways. Controlled
trials of dynamic therapy are infrequent, and there is
little evidence that they are likely to be of utility in a
significant number of patients with asthma.
6. Counseling involves talking over problems with a
health professional. In supportive counseling, the
counselor acts primarily as a good listener who
provides emotional support. Supportive therapy some-
times has a problem-solving focus and may be helpful
for patients experiencing an acute crisis.
7. Family therapy attempts to understand family
dynamics. Gustafsson and colleagues concluded that
dysfunctional family interaction seems to be the result
rather than the cause of wheezing in children.
14 There
is evidence that family therapy may improve symptoms
in children with asthma.
8. Educational approaches do not attempt to alter core
psychological processes and therefore are not psycho-
logical therapies as such. They are already the subject of
systematic reviews
15 and are routinely included as
necessary components of optimal asthma care.
9. Breathing retraining exercises include a range of
techniques for improving breathing control in asthma
(eg, Buteyko technique, yoga, and transcendental
meditation). These are not regarded as standard
psychotherapies, although aspects of breathing retrain-
ing may be included in behavioural therapy or CBT. A
Cochrane review
16 has previously examined the effec-
tiveness of breathing retraining exercises, suggesting
that conclusions must be viewed with caution.
Despite the trials of various psychological approaches
in asthma, there are no sufficiently powered studies of any
single therapy to draw conclusions regarding the utility of
these approaches for improving asthma-related outcome.
The systematic review that examined the efficacy of
psychological treatments in children with asthma included
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small and the quality was poor. The authors stated that
they could draw no conclusions regarding the effectiveness
of psychological interventions for children with asthma
because of the limited literature and variability among
extant studies. Thus, in the aggregate, the benefit of
psychological interventions for children and adults with
asthma is difficult to assess because of the diversity of
techniques used, the variety of outcomes measured, and
the absence of appropriately powered trials.
A key issue apparent from these studies is how to select
patients with asthma for psychological intervention. It may
be that a randomized controlled trial that includes any
patient with asthma who is willing to participate is not the
most appropriate design as it is roughly analogous to
including normal-weight people in a weight loss trial for
obesity. Trials in which the population is enriched to have
psychosocial distress or stress may more precisely reflect
patients who are able to benefit, by virtue of having
significant room for improvement, in the way in which
they understand the illness and themselves in relation to
the illness. Similarly, patients with very mild and well-
controlled asthma are unlikely to have much room for
improvement following a psychological intervention. It is
probable that there is nonrandom overlap between these
two groups, so the patients with the worst asthma control
will, with some frequency, be those with the worst
psychological adjustment to the illness. Examining the
benefit of psychological therapies in this group might yield
a stronger signal than in many previous trials.
Furthermore, access to good psychological therapy is
generally limited by therapist availability; therefore, such
treatment arguably will be reserved in the clinical setting
for patients with the most distress and the most to benefit
from intervention. In summary, it is unfortunately possible
that there is a reasonably sized subset of patients with poor
asthma control related to poor psychological coping but
that effective interventions for these people are not being
routinely received or even offered because the trials to date
do not allow conclusions to be made with any confidence.
Relationships between Asthma and Psychiatric Illness
Epidemiologic Associations between Asthma and
Depression
The prevalence of MDD is higher in people with asthma
relative to the general population. Individuals with allergic
disease also have higher rates of MDD than nonatopic
individuals.
17,18 The presence of atopic disease increases
the risk of depression in both men and women, although a
more substantial body of evidence exists for the latter,
19 in
whom the prevalence of MDD is generally higher. Patients
with MDD or the other common mood disorder, bipolar
affective disorder, also have an increased risk of developing
immunoglobulin (Ig)E-mediated allergic conditions,
including asthma, than the general population.
20–22
Asthma and hay fever also occur more frequently in
patients with mood disorders and their family members
than in those with schizophrenia.
23
Unfortunately, the literature on the prevalence of
psychiatric disorders in patients with asthma is complicated
by a number of issues, not the least of which is the problem
of accurately defining and detecting cases of both disorders.
There is significant variation in the rates of MDD in patients
with asthma that appears in part secondary to ascertainment
issues. Population-based studies have not reported rates of
comorbidity as high as studies that evaluated depression in a
clinical cohort of patients with asthma, for whom lifetime
rates of asthma have been recorded to be as high as 47%.
24,25
This may represent an accurate reflection of the asthma
population as it is possible that the overall rates of
psychiatric illness in those with mild and well-controlled
asthma are low, with elevated rates observed in patients
surveyed in tertiary care clinical settings who are likely to
have more severe and chronic asthma. Regardless, the fact
that individuals with asthma manifest higher rates of MDD
and vice versa suggests that the two conditions may have
shared pathogenic elements.
Familial Associations between Asthma and
Depression
Further support for a link between asthma and MDD
comes from family studies that suggest that the prevalence
of one disorder is increased in the family members of index
cases with the other. The initial evidence for this link came
from mothers whose children had asthma but did not have
MDD.
26,27 In some studies, rates of depression in family
members were related to the severity of the child’s asthma
symptoms, raising the possibility that these were related to
the stress of having an ill child.
28,29 Wamboldt and
colleagues reported that mood but not ADs were increased
in the relatives of adolescents with severe asthma and that
the onset of these problems was equally likely to have
occurred before as after the proband’s asthma diagnosis.
30
More recent studies provide further proof that the
prevalence of mood disorders is increased in the parents
of children with asthma
31 even when childhood mental
illness is considered.
32
14 Allergy, Asthma, and Clinical Immunology, Volume 4, Number 1, 2008Evidence supporting a genetic link between asthma and
depression comes from Wamboldt and colleagues’ study of
Finnish twin pairs in which they assessed the prevalence of
atopic disease and depressive symptomatology.
33 They
found a within-person correlation between atopic and
depressive symptoms of 0.103 and, using a best-fit model,
estimated that 64% of this association was due to shared
familial vulnerability, mainly additive genetic factors.
Common Environmental Risk Factors for Asthma and
Depression
Obesity
Obesity generates a systemic inflammatory milieu
34 that
increases the risk of numerous somatic conditions,
including both asthma
35 and MDD. Epidemiologic studies
suggest that there is an increased prevalence of asthma in
obese adults, that this relationship is dose dependent, and
that the link is stronger in women.
36 This association may
reflect the direct mechanical effects of obesity,
37 immune
system alterations,
38 or the effect of hormones such as
leptin
39 imposed by excess weight.
Obese individuals also appear to be at increased risk of
developing MDD.
40 The etiology of this seemingly
bidirectional relationship is unknown but likely involves
genetic and environmental influences, including the
psychological experience of being overweight, as well as
alterations in various hormones and cytokines. Although
iatrogenic and clinical disease factors are most often
implicated, it is possible that MDD and obesity share
common pathogenic factors,
41 including dysregulation of
the hypothalamic-pituitary-adrenal (HPA) axis,
42 neuro-
transmitter systems,
43,44 and/or immune function.
45,46
Smoking during Pregnancy
Maternal smoking during pregnancy has been proposed to
increase the risk of both MDD
47 and asthma.
48
Adolescents exposed to cigarette smoking in utero have
an increased risk of MDD prior to correcting for
confounding and selection factors but not after this
correction.
47,49 Smoking in pregnancy is also associated
in epidemiologic studies with an increased risk of asthma
in children, adolescents, and adults, even when confound-
ing variables are controlled for.
48 Numerous mechanisms
have been proposed to account for this relationship,
including the effects of smoking on fetal respiratory system
development,
50 lung cyclic adenosine monophosphate
(cAMP) levels, and phosphodiesterase 4 (PDE4) activity,
which together may increase airway hyperresponsiveness.
51
Interestingly, asthmatics who are currently smoking or
who have smoked in the past are relatively resistant to the
anti-inflammatory effects of glucocorticoids (GCs).
52,53
Smoking and the oxidative stress it produces can affect GC
receptor nuclear translocation and nuclear cofactors.
54,55
Cases of severe GC-resistant asthma also manifest an
increase in oxidative stress.
56 It is possible therefore that
exposure to cigarette smoke in utero has similar effects on
these pathways, increasing the risk of GC resistance and
diseases associated with GC dysregulation later in life,
including asthma and depression.
Asthma and Anxiety
Katon and colleagues conducted a review of the literature
on the relationships between asthma and anxiety in
children, adolescents, and adults.
57 They concluded that
up to one-third of children and adolescents may meet the
criteria for a comorbid AD. The rates of AD in adults with
asthma ranged from 6 to 24%, although the studies had
many of the same limitations as the studies of depression
and asthma, including issues with small samples, ascer-
tainment biases, and questionable methods of confirming
the diagnosis of asthma or AD.
A study examined not only the rates of depression and
anxiety in adolescents but also the likelihood that the
comorbid psychiatric condition was recognized and trea-
ted.
58 Only about one-third of youth with anxiety had the
condition recognized within the last year, and only about
one in five youth with MDD had adequate treatment. A
commentary accompanying this article concluded that the
methods used by Katon and colleagues were probably
conservative in the estimates of rates receiving treatment, so
the actual rates of treatment of MDD or anxiety in youth
with asthma may be even lower than 20%.
59 Thus, there
appears to be a significant dissociation between studies that,
despite limitations, suggest that anxiety and MDD occur
frequently in asthma and studies that suggest that in routine
clinical practice comorbid psychiatric conditions are infre-
quently recognized in patients with asthma and even less
frequently treated.
Treatment of Psychiatric Symptoms to Improve
Asthma and Health-Related Quality of Life
Pharmacologic Treatment
There is a notable paucity of data examining whether
treating MDD in people with asthma will improve asthma
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with asthma and an episode of depression to citalopram, a
commonly used antidepressant, or placebo.
60 The impact
of this intervention on asthma symptoms was difficult to
evaluate between antidepressant- and placebo-treated
patients because at end point there was no difference in
depression scores between antidepressant- and placebo-
treated patients. Nonetheless, antidepressant-treated
patients required fewer oral corticosteroids and there was
a correlation between asthma symptom severity and
depression symptoms. Perhaps the most interesting result
in the study was the fact that patients who had substantial
improvement in depressive symptoms (regardless of
whether they were medication or placebo treated) had
greater improvement in a variety of asthma-related scales
than patients whose depressive symptoms did not improve
significantly. These results do, therefore, support the
notion that treating depressive symptoms may improve
outcome in patients with asthma.
To our knowledge, only one other trial, conducted
several decades ago, has evaluated the impact of
antidepressant treatment on asthma outcome. In 1969,
Sanger examined whether the antidepressants amitripty-
line and doxepin improved depressive and anxiety
symptoms in patients with allergic diseases, including
some patients with asthma.
61 Doxepin appeared to have a
more potent effect than amitriptyline because the
particularly potent antihistaminergic properties of doxepin
are not known.
Behavioural Treatment
We were unable to find any studies that had focused
specifically on using psychological treatment for MDD in
patients with asthma. Given that there are time-limited
psychotherapies that are acceptable to patients, safe and
effective treatments for MDD, it is unfortunate that no
information exists on whether use of such therapies would
improve asthma as well as depressive symptoms. A recent
trial examined the benefit of CBT for patients with
somatization disorder, in which patients have a preoccu-
pation with physical symptoms that are disproportionate
to any identifiable pathophysiologic process.
62 CBT was
effective in this study, and the gains were maintained so
that at follow-up months after treatment finished, there
was evidence that patients were accessing medical
resources less often than those who had not received
CBT. These results provide indirect evidence to suggest
that patients whose limitations associated with asthma
appear greater than that predicted by the physical severity
of the illness might benefit from CBT.
Pathophysiologic Links between Asthma and
Depression
Stress and GC Resistance
The experience of significant stress early in life is a risk
factor for the development of both MDD and asthma and,
via GC resistance, may represent the most important link
between the two conditions. A subset of patients who are
exposed to psychological/emotional stress early in life have
subtle dysregulation of the sympathetic and parasympa-
thetic nervous systems and the HPA axis, including GC
resistance, which bias the immune system toward a T
helper (Th)2 response,
63,64 immune system hyperactivity,
and inflammation. It is possible that increased inflamma-
tion brings out a latent genetic risk for both asthma and
depression, with the former having either a lower thresh-
old for expression or with developmental factors interact-
ing with inflammation to produce asthma. Depression,
which, compared with asthma, is uncommon in prepu-
bertal children, may have a higher threshold for symptom
expression, requiring an increased duration of exposure or
higher levels of GC resistance.
Immune development may also be influenced by
prenatal imprinting or programming.
65,66 Stress in utero
not only results in the overexpression of cortisol in the
mother but also stimulates secretion of corticotropin-
releasing hormone (CRH) by the placenta. Such exposure
appears to alter humoral immune responses and indivi-
duals’ sensitivity to stress in postnatal life.
67 Postnatal
stress has also been implicated in the development and
exacerbation of asthma.
68 Parenting difficulties when a
child is 3 weeks old were a predictor of early-onset
childhood asthma in those predisposed to the disorder.
69
Other studies suggested that parenting difficulties,
70 but
not family stress,
71 are associated with asthma.
GCs effectively suppress asthma symptoms in most
people; however, a small number of patients fail to
respond to exogenous steroids, even when they are given
high doses.
72 Although GC-resistant patients exist on a
spectrum, they have significant illness burden and present
significant management challenges. They have usually had
asthma longer than the average patient and manifest
irreversible airflow obstruction and a greater inflammatory
burden.
73 GC signaling defects are also present in
depressed patients.
74 Nearly 50% of persons with depres-
sion have elevated cortisol levels,
75 with higher rates of
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depression
76 and a higher number of lifetime depressive
episodes.
77 Cortisol and CRH levels in cerebrospinal fluid
(CSF) are increased in depressed patients,
78,79 especially
dexamethasone nonsuppressors.
80 Somatic treatments
such as electroconvulsive therapy and medications nor-
malize elevated CRH levels.
81,82
Resistance to GCs may occur as a result of a number of
factors, with long-term exposure to inflammatory cyto-
kines often proposed as a key factor. The mechanisms
through which this occurs may involve mitogen-activated
protein kinase (MAPK), nuclear factor kB (NF-kB), and
cyclooxygenase (COX) pathways (see Pace and colleagues
for a review
83). Stressful experiences may cause the
developing autonomic nervous system (ANS) to be more
labile, which can evolve into emotionally triggered asthma
symptoms.
30
Cytokines
Cytokines affect inflammatory responses, and the processes
they govern are implicated in the pathophysiology of many
diseases, including those with CNS manifestations.
Peripheral cytokines increase glial cell release of cytokines
in the brain via the vagus and glossopharyngeal nerves
rather than acting directly on the brain themselves.
84 The
intersection of the cytokine and HPA systems is mechan-
istically relevant to the development of both asthma and
MDD.
Depression is characterized by immune activation,
particularly the innate immune system.
85 Sickness beha-
viour, the emotional and behavioural symptoms that
develop as a consequence of acute infection or cytokine
therapy, appears to be the result of increased levels of the
proinflammatory cytokines interleukin (IL)-1 and tumour
necrosis factor (TNF) and is the most frequently cited
evidence linking cytokine activation with depression. Vital
to the development of sickness behaviour is the enzyme
indoleamine-2,3-dioxygenase (IDO), which is increased in
interferon (IFN)-treated patients who become depressed
and degrades tryptophan into the neurotoxic metabolites
quinolinic acid and 3-hydroxykyurenine, which cross the
blood-brain barrier and bind glutamate receptors. IDO
appears to affect brain monoamine neurotransmission,
and this may be the mechanism by which it affects mood.
86
Proinflammatory cytokines may also induce tissue resis-
tance to GCs by inhibitory effects on the expression or
function of GC receptors, which might contribute to CRH
release secondary to reduced feedback inhibition as well as
an increase in cytokine release.
87
A number of cytokines are dysregulated in patients
with MDD, including IL-6,
88 which participates in the
transition from innate to acquired immunity and in the
polarization of immune responses from a Th1 to a Th2
type,
89 which is also of relevance to asthma development.
IL-1b appears to be increased in those with asthma
90,91
and depression
88 and in those with depression and
asthma.
92 Through IL-5, it results in increased production
of intercellular adhesion molecule 1 (ICAM-1) and
vascular cellular adhesion molecule 1 (VCAM-1) by
endothelial cells (see below).
93 IL-1b alters behaviour in
rodents, inducing anorexia, sleep disturbances, and
memory impairment; it also alters monoamine and
neuropeptide neurotransmitter metabolism.
94
High levels of TNF can exacerbate inflammatory and
pro-oxidative functions.
95 TNF levels are increased in
those with MDD
88,96 and are associated with asthmatic
complications. TNF acts preferentially on smooth muscle
cells in airways, resulting in damage to bronchial epithelial
cells as well as leakage of these and endothelial cells.
97 TNF
protein and gene expression levels appear to be increased
in the bronchoalveolar lavage fluid of asthmatics,
98 and the
TNF receptor–IgG1Fc fusion protein appears to improve
lung function in these patients.
99
Thus, despite the complexity of elucidating the role of
the cytokine system in either depression or asthma, there is
substantive evidence that the diseases share dysregulation
of some key cytokines. Whether this overlap reflects a
specific relationship or simply common states of inflam-
matory processes remains to be clarified. Unfortunately,
the same dilemma is relevant to most of the systems
discussed below.
Immune System Imbalance: Type 1 Th1 versus Th2
Phenotypes
Some propose that a reduction in exposure to microbes is
responsible for the increasing prevalence of asthma as a
lack of exposure may lead to a polarization of the allergen
specific T-cell response toward Th2 instead of Th1
immunity.
100 IL-4 is particularly important in that it
regulates IgE isotype switching, VCAM-1 production and
Th cell commitment, and allergen-induced eosinophilia in
asthmatics.
101,102 IL-5 plays an important role in eosino-
phil differentiation and survival. IL-13 is involved in
airway hyperresponsiveness in these individuals.
100
The role of Th1-Th2 cytokine balance has, not
surprisingly, been much less extensively investigated in
those with MDD. Although numerous studies have
examined plasma cytokine and immune cell levels in those
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Th1 and Th2 cytokines in this population. Pavon and
colleagues examined the serum levels of cortisol as well as
Th1 (IL-2 and IFN-c) and Th2 (IL-4 and IL-13) cytokines
in 33 unmedicated outpatients with MDD and compared
them with 33 nondepressed controls.
103 In this study, the
depressed patients appeared to have a preference for Th2
immune responses. Given that cortisol was also elevated in
this sample, and given the propensity for cortisol to
increase Th2 activity,
104 it may be that the immune shift to
a Th2 response was driven by altered activity in the HPA
axis. Mendlovic and colleagues also demonstrated a
predilection for a Th2-like profile of cytokine secretion
from the T cells of a small sample of depressed patients
compared with controls.
105
Nuclear Factor kB
NF-kB is a major transcription factor that is induced
by a large number of factors, including proinflammatory
cytokines and other mediators of stress, and plays a role in
the development of immunity. Dysregulation, including
aberrant activation of the NF-kB pathway, is seen in
numerous diseases, including asthma and MDD.
106
NF-kB exists in the cytoplasm of cells in an inactive
form bound to its inhibitor IkB. When proinflammatory
cytokines such as TNF bind their receptors, it results in
NF-kB translocation to the nucleus, which pro-
motes gene expression. It has been hypothesized that
activation of this pathway is relevant to the pathophysiol-
ogy of MDD since certain cytokines appear to contribute
to the development of depression in some individuals (see
above) and since serotonin-containing neurons, long
implicated in the development of depression, also contain
NF-kB. One group has hypothesized that cytokines’
activation of NF-kB leads to depression via increases
in 5HT1A gene expression, which result in decreased
firing of serotonin neurons and serotoninergic neuro-
transmission.
107
Asthma is also characterized by abnormal activation of
cytokines and adhesion molecules and is triggered by a
number of environmental agents, many of which result in
NF-kB activation. NF-kB appears to have an important
role in allergic inflammation,
108 and inhaled GCs have
demonstrated inhibitory effects on NF-kB.
109 It is
possible, then, that a number of factors common to the
pathophysiology of asthma and MDD, including altera-
tions in the HPA axis and cytokine dysregulation, converge
on NF-kB signaling, which may serve as a final common
pathway contributing to the development of these
disorders.
Oxidative Stress
Oxidative stress may be relevant to the pathogenesis of
asthma.
110 The capacity of the body’s natural antioxidant
system appears reduced in those with asthma in times of
disease stability,
111 as well as exacerbation.
112 Levels of
oxidative stress are elevated not only locally in airways but
also systemically,
113 and levels of oxidative stress markers
appear to correlate with disease severity.
114 Increases in
oxidative stress have also been implicated in shifting
immune responses to a Th2 phenotype.
115
Psychological stress may affect the body’s capability to
deal effectively with reactive oxygen species and increase
oxidative stress.
116,117 MDD is associated with increased
levels of reactive oxygen species,
118 and depressed people
have evidence of excess oxidative damage,
119,120 indepen-
dent of other causes of oxidative injury.
121 Those with
multiple depressive episodes appear to incur more damage
than those with fewer.
122
Increased innate immune responses
123 and inflamma-
tion
124 are also associated with MDD and can increase
oxidative stress and may contribute to or account for the
above findings. Indeed, overstimulation of the enzyme
IDO raises levels of metabolites of kynurenine and 3-
hydroxykynurenine, which increase oxidative stress.
86 It is
currently unknown whether oxidative stress contributes to
or is an epiphenomenon of the pathogenesis of depres-
sion.
125
Intracellular Adhesion Molecule 1
Intracellular adhesion molecule 1 (ICAM-1) is involved in
the leukocyte adhesion, persistent inflammation, and
cellular recruitment critical to the pathogenesis of asthma.
ICAM-1 initiates intracellular signaling events and mod-
ulates the activation and proliferation of inflammatory
cells as well as cytokine production,
126 leading to bronchial
hyperresponsiveness and airway inflammation.
127
Increases in soluble ICAM-1 are apparent in asthma
exacerbations
128 after allergen provocation
129 and correlate
with asthma severity.
130
ICAM-1 appears to be expressed in increased amounts
in the brains and serum of depressed patients
131–134 and
remains elevated even after adjustment for potential
confounders.
135 It also appears that soluble ICAM-1 levels
play a role in the development of depression in IFN-
treated patients. Patients with malignant melanoma who
developed depression on this treatment had higher soluble
ICAM-1 levels than those who did not, and the levels
correlated with depression severity. These results have been
18 Allergy, Asthma, and Clinical Immunology, Volume 4, Number 1, 2008interpreted as suggesting that increases in soluble ICAM-1
reflect the breakdown of the blood-brain barrier, which
might then allow cytokines to enter and affect mood
changes by modulating neurotransmission.
136
Whether increased levels of soluble adhesion molecules
are involved in the pathogenesis of MDD or merely reflect
a state of persistent, low-grade inflammation is not known,
but this may represent another link between depression
and asthma. Alternatively, this finding may be related to a
primary immune dysfunction with increased cytokines and
HPA axis abnormalities, which increased levels of soluble
ICAM may reflect.
Prostaglandins and COX-2
COX-2 and its metabolites exert complex effects in the
lung as some act as pro- and others as anti-inflammatory
mediators.
137 COX-2 gene expression is increased in
asthmatic patients’ airways; however, increased COX-2
activity suppresses the asthmatic response. That prosta-
glandin (PG) levels appear to be increased in those with
depression suggests that COX-2 activity is increased in
these individuals as well. Unlike most tissues, COX-2 is
constitutively expressed in the brain
138 and interacts with
immune and neurotransmitter systems there. COX-2 may
exert its effects by increasing PGE2 levels to stimulate IL-6
production. These findings may account for why treatment
with COX-2 inhibitors has been associated in a few studies
with reduced depressive symptomatology.
139,140 Activation
of COX-2 increases PGE2 concentrations, which can
stimulate the HPA axis. The COX pathway also appears
to interact with GC signaling and may modulate GC
receptor responses. Thus, it is possible that COX-2 exerts
its influence on affect via this mechanism.
83
PGs may also be involved in the pathogenesis of
asthma
141 and MDD. They are produced by almost all cell
types and participate in the inflammatory cascade that
occurs in airways.
142 PGs D2,E 2, and F2 have a variety of
effects on airway physiology, including polarizing immune
cells to a Th2 phenotype, attracting immune cells,
stimulating proinflammatory cytokines, increasing mucus
production and vascular leakage, and causing constriction
of bronchial smooth muscle.
142
PGE2 is increased in the CSF,
143 serum,
144 and saliva
145
of patients with MDD and correlates with the severity of
depression.
146 Mastocytosis, a disorder in which there is
overproduction of PGD2, often manifests depressive
symptomatology,
147 and PGs influence behaviour,
148
sleep,
149 and appetite.
150 PGE2 also appears to have a
direct effect on the promotion of sickness behaviour.
151
Phosphodiesterase 4
PDE4 is found in a number of cell types, including
neurons and immune and airway cells. Both asthma and
MDD may involve overactivity of PDE4.
152 For example,
the main gene involved in mucin secretion, MUC5AC,i s
overexpressed in those with asthma,
153 and PDE4 inhibi-
tion may ameliorate this. Rolipram, a PDE4 inhibitor,
inhibits neutrophilic and eosinophilic inflammation and
the release of cytokines from Th1 and Th2 cells, as well as
airway epithelium, basophils, monocytes, and macro-
phages.
154 Also of relevance to asthma is the fact that
PDE4 inhibitors reduce fibrosis and remodeling in the
airway via inhibition of certain matrix metalloproteinases
(MMPs). Clinically, PDE4 inhibitors reduce early and late
inflammatory response to allergens in mild to moderate
asthmatics and may produce small improvements in
forced expiratory volume in 1 second in asthmatics.
155
Second-messenger impairments affecting cell survival
and neuroplasticity are also believed to underlie MDD,
156
and cAMP-mediated signaling is implicated in the
pathophysiology of MDD.
7 PDE4 is expressed in neurons
in the hippocampus, striatum, substantia nigra, and
cerebral cortex, as well as in astrocytes and, of relevance
to depression, in the areas of the brain that are involved in
reward and affect.
157 PDE4 also participates in cAMP
pathways affected by known antidepressants.
158 Rolipram,
aP D E 4 inhibitor, has antidepressant-like effects in
preclinical animal models and plays a role in induction
of hippocampal neurogenesis,
159 which may be necessary
for antidepressants to effect behavioural change.
160
Moreover, reduced expression of PDE4 appears to protect
mice against depressive symptomatology.
161
Matrix Metalloproteinases
MMPs are proteolytic enzymes that degrade extracellular
matrix components.
162 The production and function of
MMPs are regulated by molecules such as the tissue
inhibitors of matrix metalloproteinases (TIMPs), cytokines
(eg, TNF, IL-1b), and growth factors. It is speculated that
cytokines and MMPs interact in complex ways as a means
of producing some of the symptoms of asthma.
163
MMPs may participate in airway remodeling, and
increased levels of MMP-9 have been detected in asthma,
related to elevated numbers of neutrophils and eosinophils
in the airways
162 and correlated with asthma severity. In
mouse models of asthma, MMP-9 absence is associated
with a decrease in airway infiltration by inflammatory
cells,
164 perhaps by decreasing dendritic cell migration.
165
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logic CNS states but are found in diseases of the CNS.
166
Certain MMPs can convert TNF and IL-6 to their active
forms, a mechanism by which MMPs might promote an
inflammatory milieu in the CNS.
167 Psychological stress,
mediated by activation of the HPA and sympathetic-
adrenal medullary axes, as well as cytokine alterations,
affect MMP and TIMP levels.
168
Histaminergic System
Histamine is made and released by inflammatory cells and
neurons and participates in the regulation of inflammatory
responses in several conditions, including asthma.
Histamine enhances secretion of proinflammatory cyto-
kines, including IL-1a and -1b, IL-6, and a number of
chemokines.
169 Histamine acts as a chemoattractant for
eosinophils and mast cells and is released from mast cells
during allergic reactions. Moreover, it appears to shift the
immune response to Th2 dominance.
170 Histamine
exposure causes bronchoconstriction in all humans,
although asthmatics are more sensitive to this effect than
nonasthmatics, and treatment with H1 receptor antago-
nists has been shown to improve symptoms and
pulmonary function and may delay asthma onset in
high-risk individuals.
171–173
Histamine also acts as a neurotransmitter in the brain
and has been proposed to be involved in the pathogenesis
of depression
174 as histamine type 3 receptor blockers may
have antidepressant effects.
175 Alterations in histaminergic
activity may also contribute to the experience of mental
and physical fatigue experienced by depressed
patients.
25,176
Adenosine
Adenosine is an endogenous nucleoside present at low
levels under normal conditions; however, its concentra-
tions increase in the setting of stress and inflammation.
177
Adenosine has proinflammatory and immunomodulatory
effects and may be involved in the pathogenesis of
asthma.
178–180
Increased adenosine levels may result in depressive
symptoms. The involvement of adenosine in the patho-
physiology of mood disorders was first proposed when
increases in endogenous adenosine levels led to behaviour
consistent with learned helplessness and behavioural
despair in laboratory animals.
181,182 Antagonists to ade-
nosine receptors, particularly A2A antagonists, appear to
have antidepressant properties,
183 which may be mediated
by increases in dopaminergic transmission in the frontal
cortex.
184
Nitric Oxide
Nitric oxide (NO) is the only molecule in the body that
acts as a hormone, reactive oxygen species, and neuro-
transmitter. The neurotransmitter and vasodilatory actions
of NO are mediated mainly by guanylate cyclase activation
in cells, which leads to an increase in the production of
cyclic guanosine monophosphate and its dependent
kinases.
185 Some evidence suggests that NO may be
involved in the pathogenesis of asthma.
186 Evidence
supports the role of NO in the pathogenesis of depression
and in a number of the symptoms of this syndrome,
including cognitive difficulties, sleep, and alterations in
appetite.
185,187 In the brain, neuronal nitric oxide synthase
(NOS) produces NO after activation of the N-methyl-D-
aspartate receptor by glutamate
185 and acts as a modulator
of the HPA axis.
188 Neuronal NOS production is also
regulated by GCs in the hippocampus, suggesting that it
has a role in the body’s response to stress.
187 It appears to
be colocalized with a number of neuropeptides in the
hypothalamus, including arginine vasopressin, CRH, and
oxytocin. Neurons in the prefrontal cortex, amygdala,
189
and the serotoninergic cells of the dorsal raphe nucleus
also contain NOS.
190
Neuropeptides
Many neuropeptides exist and have been implicated in the
pathophysiology of inflammatory diseases, although we
limit our discussion to those mediators that appear to be
of relevance to both asthma and MDD. The airway is
innervated not only by sympathetic and parasympathetic
nerves but also by sensory nerves referred to as the
noncholinergic-nonadrenergic that originate mainly from
the vagal ganglia. Not surprisingly, a bidirectional relation-
ship exists between the airway surface and the nerves that
innervate it, and neuropeptides appear to mediate this
relationship.
191
Tachykinins are proinflammatory neuropeptides of
which substance P (SP) and neurokinin A (NKA) are
members. They regulate neurogenic inflammation in the
airway.
192 SP binds NK1 receptors located mainly in the
airway epithelium, submucosal glands, and vessels,
whereas NKA binds NK2 receptors found predominantly
on smooth muscle cells.
193 NKA constricts airway smooth
muscle cells with particularly potent effects in smaller
airways, producing bronchoconstriction in asthmatics,
194
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induces inflammation and hyperresponsiveness of air-
ways.
195 Despite the theoretical appeal of blocking
tachykinin receptors, human testing with antagonists has
been met with mixed results.
191 However, this may be in
part due to difficulties with drug delivery.
Neuropeptides function as neurotransmitters and
neuromodulators and are involved in the regulation of
emotion and responses to stress.
196 Thus, they have
become attractive targets for manipulation with regard to
mood disorders. Indeed, SP receptor antagonists have been
demonstrated to possess antidepressant effects in double-
blind randomized controlled trials. Antagonists to NK1,
the main tachykinin receptor in the human brain, appear
to have some antidepressant efficacy in treating humans
with depression and anxiety.
197
ANS (Parasympathetic Division)
Efferent parasympathetic fibres of the vagus regulate
numerous functions, whereas afferent fibres (comprising
80% of the nerve) carry sensory information from the
head, neck, abdomen, and chest. Messages are carried to
the dorsal medullary complex, particularly the nucleus
tractus solitarius, which relays information to other brain
regions, including the locus ceruleus and raphe nucleus, as
well as limbic, paralimbic, and cortical regions. The
parabrachial nucleus also relays information to the
hypothalamus, amygdala, and thalamus.
198
Some have suggested that depression produces a state
that favours airway constriction in those with asthma.
Depression appears to be a state of cholinergic dominance
and asthma a condition marked by cholinergic dysregula-
tion.
199 This hypothesis is supported by evidence that
shows that some antidepressants result in bronchodilation
in laboratory animals.
200 In animals in which hopelessness
is induced, cholinergic tone in the ANS increases.
201
Another study reported that children who died of asthma
had states of hopelessness in the days preceding their
deaths, postulated to have contributed to mortality via
ANS dysregulation manifested as increased cholinergic/
vagal activation in sad and hopeless individuals.
202 In
1997, Miller and Wood reported that higher levels of
induced sadness were associated with greater vagal and
presumably cholinergic activation, reflected by increased
heart rate variability (HRV) and oxygen saturation
variability than happiness in 24 children aged 7 to 18
years.
203 They suggested that this supported the theory
that sadness could evoke autonomic patterns that
could mediate airway constriction. This work supported
previous findings of increased cholinergic/parasympathetic
tone in those experiencing hopelessness/depression
201
and Miller and Wood’s previously hypothesized model
implicating mood-associated vagal mediation of pulmon-
ary function.
203
The increased reactivity of asthmatic patients’ airways
may be secondary to abnormal ANS control.
204 The
parasympathetic/vagal component in particular appears to
be relevant to asthma pathogenesis as it is involved in
bronchoconstriction secondary to exercise and alterations
in airway surface temperature. Asthma is related to
abnormal ANS function, including both bronchial hyper-
reactivity to cholinergic drugs and reduced sensitivity to
adrenergic dilators. Alterations in autonomic function
have also been noted in asthmatics following exercise
relative to nonasthmatic individuals. Enhanced cholinergic
airway responsivity has also been postulated to contribute
to the development of asthma.
205
The literature examining HRV in patients with
depression has been mixed, with some
206,207 but not
all
208,209 studies suggesting that HRV is lower in depressed
patients, in keeping with excessive sympathetic modula-
tion of the heart rate or inadequate parasympathetic
tone. Moreover, vagal nerve stimulation (VNS), an
experimental treatment for depression in which the vagus
is stimulated, sheds some doubt on whether excess
parasympathetic stimulation contributes to depressive
symptoms. There is some evidence, however, that VNS
therapy may have effects on the airways of certain
individuals.
210
Thus, it is possible that frequent experience of the
emotional states of sadness and hopelessness, common in
those with MDD, may mediate, via increased cholinergic
activity, an increased risk of asthma in some individuals,
although it has been proposed that the enhanced
cholinergic responses may be secondary to asthma rather
than a pathogenetic contributor.
Risk of Treatment?
Little attention has been paid to the effects that treatments
for either asthma or MDD have on the risk of development
of the other. Serotonin has been controversially implicated
in the pathophysiology of asthma, and patients with
symptomatic asthma display increased plasma serotonin
levels relative to asymptomatic individuals.
211
Serotoninergic receptors present in human airways, when
activated, appear to stimulate IL-6 release in these cells.
212
Moreover, serotonin may have immunomodulatory
effects.
213 Reports requiring replication suggested that
Lieshout and MacQueen, Psychological Factors in Asthma 21tianeptine, a selective serotonin reuptake enhancer,
reduces respiratory symptoms in asthmatics.
214 Although
it is therefore conceivable that selective serotonin reuptake
inhibitors could trigger or worsen asthmatic symptoms via
release of IL-6, there are no clinical data to support this.
However, tianeptine also appears to have antidepressant
effects and may modulate asthma symptoms via this
mechanism.
The long-term treatment of asthma and not the
experience of asthma itself may also contribute to the risk
of developing depression in asthmatics. It has been
suggested that corticosteroid treatment taken for a number
of indications is associated with depressive symptoms,
215,216
although these results are limited by the fact that the
indications and route of steroid treatment were not known.
Thus, it is also possible that in a subset of patients with
asthma, perhaps those treated recurrently with oral
corticosteroids, that treatment contributes to or accounts
for an increase in the rates of MDD seen in this population.
CNS Correlates of Asthma
It is increasingly accepted that psychological stress can
modulate asthma symptoms.
217,218 There is anecdotal and
empirical evidence that the stable variable of nonhypnotic
suggestibility can determine the susceptibility of asthmatic
patients to suggestion of bronchoconstriction, providing a
construct for understanding how some, but not all,
patients with asthma might be particularly influenced by
asthma-related cues.
219 Until recently, however, there were
no studies that directly imaged the brain during exposure
to asthma-related stimuli.
In a seminal study, Rosenkranz and colleagues used
functional magnetic resonance imaging (fMRI) to examine
activity in the anterior cingulate cortex (ACC) and insula
during exposure to asthma-related words when patients
with asthma were exposed to allergen.
220 Although there
was a small sample of patients, the results provide
provocative evidence that these brain regions were
hyperresponsive to asthma-related emotional cues and
afferent physiologic signals. The ACC receives input
regarding key physical symptoms (eg, shortness of breath)
of relevance to asthma (for an extensive review of the ACC,
see Devinsky and colleagues
221). Along with the insula, the
ACC is also crucial for the processing of emotional stimuli
and is implicated in the pathophysiology of MDD.
Rosenkranz and colleagues contextualized their study by
stating that ‘‘despite the compelling support for a model
integrating psychological and physiological factors in
asthma, the brain has been largely absent from any
discussion of its mechanistic underpinnings.’’
220
Capuron and colleagues also used fMRI in patients
receiving IFN therapy and found that IFN-treated patients
had activation of the dorsal ACC during a visuospatial task
that was not present in control subjects.
222 Interestingly,
IFN-treated patients performed well on the task but
a p p e a r e dt or e q u i r em o r ee x t e n s i v ei n v o l v e m e n to f
the ACC than was necessary from control subjects.
Although indirect, this study supports the hypothesis
that the ACC may be important for understanding
the interface of cognition, emotion, and peripheral
inflammation. Furthermore, a study of patients with
damage to the ACC found that they had impaired
autonomic cardiovascular responses in response to mental
stress.
223 Studies such as these, which integrate brain
imaging with physiologic symptoms or inflammatory
markers, are complex to undertake but represent extra-
ordinary opportunities to reveal the role of the brain in
modulating various components of the asthmatic
response.
Conclusions
Studies of psychological intervention in patients with
asthma are limited in their interpretation by the hetero-
geneity of patient samples, intervention technique, and
outcome measures. It is possible that more focused trials of
patients with measurable degrees of stress, depression, or
psychosocial dysfunction would yield a more definitive
answer regarding whether targeting psychological factors
in at-risk patients can improve asthma outcome.
Asthma and stress-related psychiatric disorders share a
number of environmental risk factors and pathophysiolog-
ic mechanisms. Perhaps the most persuasive of these is the
early experience of stress and its effects on GC resistance as
a vulnerability and prognostic factor for both depression
and asthma. There are many physiologic points of
intersection between asthma and MDD, however, and
the specificity of these associations remains to be
determined. Preliminary but promising studies are using
functional imaging modalities to examine the CNS
response to bronchoconstriction and allergen challenge.
Further studies that also examine respiratory, immune,
and neuronal responses to challenge may uncover relations
between central and peripheral effects that clarify the
relationships between cognitive and emotional events and
asthma and point toward pharmacologic and nonpharma-
cologic strategies for improving the outcome of asthma.
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